Related references
Note: Only part of the references are listed.PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations
Filip Janku et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Metformin in cancer: translational challenges
Ryan J. O. Dowling et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2012)
Stathmin Overexpression Identifies High-Risk Patients and Lymph Node Metastasis in Endometrial Cancer
Jone Trovik et al.
CLINICAL CANCER RESEARCH (2011)
Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group
Amit M. Oza et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC CTG)
Helen J. Mackay et al.
EUROPEAN JOURNAL OF CANCER (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance
Nathan T. Ihle et al.
CANCER RESEARCH (2009)
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Georg Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation
H. B. Salvesen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole
Stefania Bellone et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2008)
Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma
Karen H. Lu et al.
CLINICAL CANCER RESEARCH (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
PIKK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia
Monica Prasad Hayes et al.
CLINICAL CANCER RESEARCH (2006)
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma
K Oda et al.
CANCER RESEARCH (2005)
The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers - a study of the National Cancer Institute of Canada Clinical Trials Group
BBY Ma et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2004)
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A gynecologic oncology group study
GF Fleming et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
M Guba et al.
NATURE MEDICINE (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Hormonal treatment of endometrial cancer
G Emons et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2000)
Spindle assembly and the art of regulating microtubule dynamics by MAPs and Stathmin/Op18
SSL Andersen
TRENDS IN CELL BIOLOGY (2000)
Share Paper
